The liver has the unique capacity to regenerate in response to a damaging event. Liver regeneration is hereby largely driven by hepatocyte proliferation, which in turn relies on cell cycling. The hepatocyte cell cycle is a complex process that is tightly regulated by several well-established mechanisms. In vitro, isolated hepatocytes do not longer retain this proliferative capacity. However, in vitro cell growth can be boosted by immortalization of hepatocytes. Well-defined immortalization genes can be artificially overexpressed in hepatocytes or the cells can be conditionally immortalized leading to controlled cell proliferation. This paper discusses the current immortalization techniques and provides a state-of-the-art overview of the actually available immortalized hepatocyte-derived cell lines and their applications. Ó 2014 European Association for the Study of the Liver. Published by Elsevier B.V.
Introduction
In the field of hepatology, when orthotopic liver transplantation is not possible, human primary hepatocytes represent the 'gold standard', in particular for the establishment of bioartificial liver (BAL) support systems [1, 2] . They also serve as an important tool in research and are of particular interest for in vitro pharmacotoxicology [3, 4] . Consequently, there is a considerable and increasing demand for human primary hepatocytes, yet their use is hampered by inadequate supply, high cost, high variability and low in vitro proliferation capacity. These constraints have prompted a large-scale search for alternative cell sources, such as hepatic cell lines and stem-cell derived hepatocytes [2, [5] [6] [7] [8] [9] . In contrast to primary cells, cell lines are readily available, and usually have an unlimited growth potential and high reproducibility [10, 11] . Hepatic cell lines are either derived directly from liver tumor tissue or artificially generated from primary hepatocytes in vitro [5, 6] . Several hepatoma-derived cell lines preserve some liver-specific functions, but most of them, with exception of the HepaRG Ò cells, do not exhibit sufficient functionality to be of pharmaco-toxicological relevance [12] [13] [14] [15] [16] [17] [18] . Immortalized hepatocytes are typically derived from healthy primary hepatocytes by using a defined immortalization strategy. Both fetal and adult hepatocytes from different species have already been successfully immortalized, whether or not using a combination of viral oncogenes and the human telomerase reverse transcriptase (hTERT) protein [7, 9, [19] [20] [21] [22] [23] [24] [25] . The purpose of this paper is to discuss the different current immortalization strategies and to provide an overview of the actually available immortalized hepatic cell lines and their applications. To fully understand these immortalization techniques, the processes of hepatocyte proliferation and senescence are briefly outlined in the preceding part.
Key Points
Hepatocyte immortalization strategies
•
Commonly used immortalization genes include viral oncogenes and hTERT
• Gene transfer is accomplished by viral and non-viral methods
• Conditional immortalization enables the production of growth-controlled cell lines
Hepatocyte proliferation
Priming phase and commitment to hepatocyte cell cycle progression
Under normal conditions, the adult liver has very little proliferative activity. However, upon partial removal of liver tissue, the remaining intact hepatic lobes start to grow and liver mass is restored within seven to ten days due to the proliferation of mature hepatocytes [26, 27] . Multiple genes involved in cytokine networks become differentially expressed and regulate the initiation of this liver regeneration, a process called the ''priming phase'' [28] [29] [30] . During this step, G0/G1 cell cycle transition and early G1 progression are accomplished and hepatocytes become responsive to mitogenic signals, which leads to deoxyribonucleic acid (DNA) replication [28, 30, 31] . During collagenase perfusion of the liver, a critical step in the isolation procedure of hepatocytes, the messenger ribonucleic acid (mRNA) levels of the proto-oncogenes c-Jun and c-Fos rapidly increase, suggesting that enzymatic liver dissociation triggers the G0/G1 cell cycle transition of hepatocytes [32, 33] . Indeed, collagenase perfusion of the liver, which is accompanied by release of the cytokine tumor necrosis factor a as well as activation of the intracellular nuclear factor kappa-light-chain-enhancer of activated B cells and mitogen-activated protein kinase (MAPK) pathways, can The hepatocyte cell cycle, as in other eukaryotic cells, is composed of four phases namely the G1, S, G2, and M phase. Under physiological conditions, most hepatocytes in the adult liver escape the active cell cycle and enter a quiescent stage, known as the G0 phase. In this state, hepatocytes do not proliferate, but remain metabolically active. Upon appropriate stimulation, hepatocytes re-enter the cell cycle in the G1 phase [42, 174] . Progression through the mid-late G1 phase is growth factor-dependent. Once beyond the mitogen-dependent restriction point (RP), the cell cycle is completed autonomously, driven by the sequential activation of a series of structurally related serine/threonine protein kinases, the cyclin dependent kinases (cdk) [42] . In contrast with other mammalian cells, hepatocytes possess active cyclin A-cdk1 and cyclin B-cdk1 complexes during the S-phase of their cell cycle, which is suggested to allow rapid and efficient hepatocyte proliferation [175] . (B) The kinase activity of the cdks is tightly regulated by several different mechanisms, including binding to cyclins, binding by cdk inhibitors (cdki) and various phosphorylation/dephosphorylation events. For example full activation of the cyclin B-cdk1 complex requires its phosphorylation (P) on threonine 161 by the cdkactivating kinase (CAK). Other phosphorylation/dephosphorylation events fine-tune kinase activity and thereby facilitate proper mitotic action. The kinases Myt1 and Wee1 negatively affect kinase activity by phosphorylating cdk1 on threonine 14 (T14) and tyrosine 15 (Y15), whereas cdc25 phosphatase restores kinase activity by dephosphorylation of the same amino acids. Furthermore, Cip/Kip cdki can bind to the cyclin B/ckd1 complexes and inhibit their action [39, 42, 51, 55] . Adapted from [28, 42, 51] . CAK, cdk-activating kinase; cdk(i), cyclin dependent kinase (inhibitor); G, gap; M, mitosis; P, phosphorylated; RP, restriction point; S, synthesis; T, threonine; Y, tyrosine. Fig. 2 . Hepatocyte immortalization strategies. Several hepatocyte immortalization strategies are available, including transduction or transfection of prototypical immortalization genes. Conditional immortalization by temperature-based regulation, recombinase-based control and transcriptional regulation have been introduced to establish growth-controlled cell lines. Adapted from [10] . rtTA, reverse tetracycline transactivator; TRE, tetracycline responsive element; tTA, tetracycline transactivator.
induce priming of quiescent hepatocytes [28, 32, [34] [35] [36] . When the freshly isolated hepatocytes are plated, the sequentially increased expression of other proto-oncogenes, such as JunB, JunD, c-Myc, p53 and c-Ki-ras, indicates that the hepatocytes can proceed to the mid-late G1 phase [28, 32] . However, further progression towards the G1/S cell cycle boundary is only possible after stimulation with appropriate growth factors to overcome the mitogen-dependent mid-late G1 restriction point [32] . This major checkpoint is regulated by the tumor suppressor retinoblastoma protein (pRB) and controls whether the cellular environment supports proliferation [37] [38] [39] . The need for mitogenic signals to pursue cell cycling has also been shown in vivo, though intrinsic differences exist between the in vivo and in vitro conditions [31, 40] . In vivo, normal adult hepatocytes return to the G0 state in the absence of growth factor stimulation, but that is not the case in vitro [26, 36, 40] . After attaching to the culture dish, surviving cells remain at the mid-late G1 restriction point, do not proliferate and die early [36, 41] .
Several studies designated cyclin D1 as the major intracellular mediator of the mitogenic signals responsible for the regulation of hepatocyte proliferation [32, 40, [42] [43] [44] [45] . As such, overexpression of D-type cyclins seems sufficient to overcome the mid-late G1 restriction point and trigger hepatocyte proliferation both, in vivo and in vitro, in the absence of mitogens [43, 45, 46] . Though, the latter has been challenged by Wierod et al. [47] . Interestingly, fetal hepatocytes, which express both cyclin D2 and D3, possess a high proliferation rate that is, at least partly, independent of mitogenic pathways and characterized by the constitutive phosphorylation of pRB [48, 49] .
Critical growth factors involved in hepatocyte cell cycling include hepatocyte growth factor (HGF), epidermal growth factor (EGF), transforming growth factor (TGF) a, heparin-binding EGFlike growth factor and amphiregulin [29, 50] . Once past the midlate G1 restriction point, hepatocytes are irreversibly committed to replicate and no longer require growth factors to complete the first cycle of cell proliferation [40, 42] . From this point onwards, progression through the cell cycle proceeds autonomously and is driven by the sequential formation, activation and destruction of a series of structurally related serine/threonine protein kinase complexes, each composed of a regulatory and a catalytic subunit, cyclin and cyclin-dependent kinase (cdk), respectively [28, 42] .
Hepatocyte cell cycle regulation and control
To date, at least 20 different cdk proteins and 30 cyclins have been identified in mammalian cells. However, only some are involved in cell cycle regulation [28, 51, 52] . Whereas the cdks are expressed throughout the hepatocyte cell cycle, with the notable exception of cdk1, most cyclins display a temporal expression profile, leading to periodic activation of their respective cdk counterparts [36, 42, 53] . Since these individual cyclin/ cdk complexes perform unique functions in the cell cycle, their sequential assembly and activation dictates the order in which the cell cycle events occur [28, 51, 54, 55] (Fig. 1) . Nevertheless, subsequent progression through the S, G2 and M phases can be impeded by additional cell cycle checkpoints, which are switched on in response to unfavourable conditions [42] . In this context, checkpoints at the G1/S and G2/M boundaries ensure the orderly unfolding of different cell cycle events and inhibit cell cycling in response to DNA damage. Overall, mechanisms associated with activation of the p53/p21 pathway and suppression of the cdc25 family phosphatase activity are initiated, which results in reduced cdk activity and cell cycle arrest [38, 42, 55] . Indeed, in addition to cyclin binding, cdk activity is also regulated by a critical phosphorylation/dephosphorylation equilibrium and counteracted by cell cycle inhibitory proteins, called the cdk inhibitors (cdki) [42, 51, 55] (Fig. 1 ). Based on their structure and the identity of their cdk targets, two families of cdki have been described, namely the Ink4 family and the Cip/Kip family. The former comprises four distinct proteins, namely p15, p16, p18, and p19, which are specific inhibitors of cdk4/6. The Cip/Kip family proteins, including p21, p27, and p57, bind and inhibit different cdk/cyclin complexes [42, 55] .
Hepatocyte senescence
Following partial hepatectomy (PH), the remaining hepatocyte population needs to divide on average 1.6 times before the normal liver mass is restored and the regeneration is put back on hold [26, 31, 56] . It has been suggested that TGFb and activin A, known inhibitors of hepatocyte proliferation, as well as extracellular matrix-driven signals, underlie the termination of hepatocyte growth when the liver regeneration is completed [57] [58] [59] . During chronic liver injury, human hepatocytes are repeatedly stimulated to proliferate due to iterative waves of liver destruction and regeneration [60] . This in vivo proliferation capacity was further highlighted by the efficient repopulation of Fah
À/À mice with human adult hepatocytes for at least four sequential rounds [61] . However, human hepatocytes cannot proliferate indefinitely. Liver cirrhosis is accompanied by a significant rate of hepatocellular senescence and characterized by considerable short hepatocyte telomeres [60] . In humans, telomerase activity of most cell types is repressed early during development. Consequently, telomere DNA in proliferating somatic cells undergoes progressive attrition. Once a critical minimal length is reached, cellular growth is arrested irreversibly, a process known as replicative senescence, which was first described by Hayflick and Moorhead nearly 50 years ago [2, [62] [63] [64] . One way to overcome telomere-dependent senescence is by reactivating the telomerase activity with exogenous hTERT [65] [66] [67] . In contrast to humans, rodents display substantial telomerase activity in several somatic tissues, including the liver [62, [68] [69] [70] [71] . Their telomerase activity increases 24 h after PH and is enhanced by the preoperative treatment with EGF and HGF, but repressed by MAPK kinase inhibitors [72] . In primary rodent hepatocyte cultures, upregulation of telomerase activity was only notable or further enhanced after addition of growth factors to the culture medium [70, 72] . The high regeneration capacity, characteristic of rodent livers, may be linked to this strong telomerase activity [71] . In this regard, serially transplanted adult mouse hepatocytes have been demonstrated to divide as many as 69 times [31, 73] .
However, in vitro, both human and rat adult hepatocytes do not possess spontaneous cell growth and their proliferation capacity remains usually quite limited even when cultured under growth promoting conditions [31, 36, 68, [74] [75] [76] . The in vitro premature growth arrest, observed in primary hepatocyte cultures could be related to a telomere-independent senescence mechanism, which remains to be fully elucidated, but is suggested to involve tumour suppressor proteins and cdkis [63, 77] . Indeed, Review several studies support the contribution of cdki p21 and/or p16 to the inhibition of DNA synthesis in primary hepatocyte cultures [78] [79] [80] [81] [82] . In this respect, it was demonstrated that the second cell cycle G1 block caused by chronic MAPK pathway activation in mitogen stimulated primary hepatocyte cultures is partly related to p21 induction. Of note, transient MAPK pathway inhibition allows the establishment of multiple replication rounds in these hepatocyte cultures [79] .
Hepatocyte immortalization strategies
Immortalized hepatocytes are defined as a population of indefinitely dividing parenchymal cells that retain critical liver functions [68] . Since mature hepatocytes normally possess only limited growth potential when stimulated in vitro, immortalization strategies have been developed based mainly on the transduction or transfection of hepatocytes with well-known immortalizing genes. The most frequently used immortalization methods are (i) overexpression of viral oncogenes, (ii) forced expression of hTERT, or (iii) a combination of both [9, 68] . Moreover, some other immortalization genes as well as conditional approaches for hepatocyte immortalization have been described (Fig. 2, Tables 1 and 2 ).
Immortalization genes
Viral oncogenes Viral oncogenes include the adenoviral E1A/E1B genes, the simian virus 40 large T antigen (SV40 Tag) and the human papillomavirus 16 (HPV16) E6/E7 genes [68] . All of them have been used to establish hepatocyte-derived cell lines, such as C8-B, HepLL, HHL, AdPX3/4, Fa2N4, HepLi-4, and NKNT-3, suggesting that overexpression of viral oncogenes may be sufficient to overcome the premature in vitro growth arrest of cultured hepatocytes [19, 25, [83] [84] [85] [86] [87] . These viral oncogenes typically interfere with cell cycling by inhibiting the p16/pRB and p53 pathways [39, 68] . Hepatic cell lines have also been developed from livers of transgenic rodents overexpressing the SV40 Tag [88] [89] [90] . While the use of viral oncogenes, such as SV40 Tag, has been shown to be sufficient to immortalize rodent cells, overexpression of these oncogenes in human cells most likely only extends lifespan. Immortalization per se requires telomerase reactivation either through mutations or by the use of a second immortalizing gene, hTERT [2, 10, 20, 23, 68, 91, 92] . Furthermore, the use of a combined strategy involving a viral oncogene and hTERT, has also been reported to produce more genetically stable cells [11, 67, 68, 93, 94] . Indeed single use of viral oncogenes has often been demonstrated to induce chromosomal abnormalities [95] [96] [97] [98] [99] [100] [101] . Even though karyotype analysis of newly produced hepatic cell lines has not routinely been performed, chromosomal abnormalities have been described in different cell lines even with combined immortalization [20, 21, [102] [103] [104] . It is important to mention, however, that activation of an additional oncogene, such as Ras is usually needed to observe tumourigenicity [84, [105] [106] [107] .
Human telomerase reverse transcriptase
The single use of hTERT for immortalization has been suggested to avoid some of the genetic and phenotypic instabilities related to the use of oncogenes but is limited to a number of human cell types, including fetal and neonatal hepatocytes [2, 6, 7, 9, 10, 108, 109] . Unlike adult hepatocytes, these immature cells can still proliferate in vitro and hence do not need cell cycle stimulation for immortalization [2, 6, 7, 9, 49, 109] . However, fetal and neonatal human hepatocytes do not possess indefinite growth potential because inactivation of telomerase causes replicative senescence. Consequently, they require overexpression of hTERT to become immortalized [2, 7, 9, 109] .
Contradicting results have been reported when only hTERT was used for immortalization of human adult hepatocytes [20, 110, 111] . As telomerase activity probably does not allow adult hepatocytes to overcome the proposed telomere-independent growth arrest, overexpression of hTERT may be insufficient to drive adult hepatocytes through the cell cycle [5, 7, 66, 68] .
Miscellaneous immortalization genes
Specific combinations of immortalization genes, such as SV40 Tag with hTERT and B lymphoma Moloney Murine Leukemia virus (Mo-MLV) insertion region 1 homolog (Bmi-1), have been used to immortalize mature human hepatocytes. Bmi-1, like the viral oncogene HPV16E7, is involved in the inactivation of the p16/ pRB pathway. On the other hand, simultaneous transduction with Bmi-1 and hTERT appears insufficient to immortalize the nondividing hepatocytes [23] . Likewise, a combined HPV16E7/hTERT approach did not promote unlimited growth of human adult hepatocytes [20] . A particular cell line has been produced by co-transfection of human adult hepatocytes with p53 and pRB antisense constructs and plasmids that include E2F and cyclin D1 genes [112] . Furthermore, it seems that the hepatitis C core protein can also specifically immortalize mature human hepatocytes [10, 113, 114] . This core protein is able to induce c-Myc and cyclin D1 expression in primary human hepatocytes via activation of the signal transducer and activator of transcription-3 pathway [115] .
In general, most of the generated hepatocyte-derived cell lines are not tumorigenic, but display reduced or only limited liverspecific functionality [7, 20, 102] . Taking into account that proliferation and differentiation are mutually exclusive in vitro, it has been shown that overexpression of the cdki p21 and the use of conditional immortalization strategies can stimulate to some extent differentiation of the cells [6, 23, 84, 85, 102, 111, [116] [117] [118] [119] [120] . Other anti-dedifferentiation strategies developed to counteract the loss of functionality in primary hepatocyte cultures, including co-culture systems and overexpression of liver-specific genes have also proven useful [121, 122] .
Conditional immortalization strategies
Conditional immortalization enables the development of growthcontrolled cell lines. At least three strategies have been reported to conditionally immortalize hepatocytes, namely (i) temperature-based regulation, (ii) recombinase-based regulation and (iii) transcriptional regulation. All these methods rely on the observation that hepatocyte proliferation only takes place when immortalizing genes are expressed [10] (Fig. 2, Tables 1 and 2 ).
Temperature-based regulation
This method uses a temperature-sensitive SV40 Tag mutant. The immortalizing gene is expressed and active only at the permissive temperature (33°C), leading to the proliferation of hepatocytes. At higher temperatures (37-39°C), the immortalization gene is inactivated and cell cycle progression is no longer stimulated [10] . As no other temperature-labile immortalizing genes have yet been identified, this method is confined to SV40 Tag [10] . Moreover, the use of this strategy is not accompanied by the excision of the immortalization gene from the genome and thus could present a potential risk of tumorigenesis [84, 106, 123] . Nevertheless, some conditionally immortalized hepatic cell lines are based on this principle, and these cell lines can be transplanted efficiently in rat models of acute liver failure and chronic hepatic encephalopathy, usually without occurrence of tumourigenicity [88, 90, 102, [118] [119] [120] 124, 125] . However, concerns related to tumourigenicity form an important restriction to the clinical appreciation of immortalized human hepatocytes [20] . Importantly, the temperature shift associated with this methodology might induce changes in cellular properties, which can complicate the interpretation of the study outcome. A more sophisticated system, based on recombinase regulation, is thought to offer a solution for these issues [10, 88, 118, 126, 127] .
Recombinase-based control
The site-specific recombinase strategy uses recombinase expression to excise chromosomal DNA segments flanked by two recombination sequences and thereby irreversibly reverts immortalization [10, 128] . Numerous site-specific recombination systems, including the Cre-loxP and the FLP-FRT system, have been used to establish reversible immortalization. These systems have different efficiencies, whereby the Cre-loxP system stands out [123, 128] . In this system, immortalization genes are flanked by two identical DNA sequences, called LoxP sites. The excision of these genes is regulated by Cre recombinase [68, 123] . Proper reversion thus depends on the efficient transfer of the recombinase gene [10] . More recently, a new method based on tamoxifen-mediated self-excision has been established, rendering secondary virus-mediated transfer of the recombinase gene superfluous [87, 110, 111] . Furthermore, the suicide gene herpes simplex virus thymidine kinase (HSV-TK) has been introduced in the recombination construct as negative selection marker. Using this strategy, cells that still express the immortalization gene and HSV-TK gene, due to improper recombination, can be eliminated by exposure to ganciclovir [23, 123] . Reversible immortalization of numerous hepatocyte-derived cell lines, including C8-B, NKNT-3, IHH, and 16T-3 depends on this recombinase-based control approach [23, 84, 85, 110, 111, 129, 130] .
Transcriptional regulation
In this method, immortalization reversibility is obtained by transcriptional control of immortalization gene expression and not by recombinase activity. In this way, the risk of chromosomal rearrangement is avoided and repeated cycles of hepatocyte proliferation and growth arrest are allowed [10, 126, 127] . Transcription of immortalizing genes can be controlled by using an artificial promoter/transactivator system, such as the well-known tetracycline system [10] . Two approaches are currently available, the tet-off and the tet-on system, which are composed of a tetracycline-regulated promoter and a tetracycline transactivator (tTA) or reverse tetracycline transactivator (rtTA), respectively. When doxycycline is added to the cell culture medium, it binds to the transactivator. In the tet-on systems, bound rtTA interacts with the tetracycline-regulated promoter and induces the expression of the regulated gene. When using the tet-off method, immortalization genes are expressed in the absence of doxycycline, since only unbound tTA can interact with the gene promoter [126, 131] . The tet-on approach has been successfully used to produce a fetal liver cell line [7] . A drawback of this method, however, is the possible leaky transgene expression caused by undesired rtTA-tetracycline promoter binding in the absence of doxycycline [126, 131] . A tighter regulation of the transgene expression can be obtained by combining the rtTA system with a tetracycline-controlled transcriptional silencer [131] .
Gene transfer
An effective gene transfer method is of utmost importance for immortalizing hepatocytes [91] . Different non-viral and viral methods have been used to generate immortalized hepatocytederived cell lines, namely plasmid transfection, viral transduction and the use of human artificial chromosomes (Table 2) .
Plasmid transfection
Various approaches are available for transfecting plasmids into primary hepatocytes [91, 132] . Due to immortalization, stably transfected cells are selected, allowing simple transfection procedures to be used [132] . Examples of common transfection methods that have been used to immortalize hepatocytes include calcium phosphate precipitation and electroporation [24, 25, 133, 134] . However, both approaches typically display low gene transfer efficiencies and high hepatocyte toxicity [91, 132] . Replacement of calcium by strontium eliminates toxicity but the gene transfer efficiency remains low [91] . Other researchers explored liposomes as gene carriers for hepatocyte immortalization [21, 83, 112, [135] [136] [137] . When properly optimized, lipid-mediated gene transfer can achieve high gene transfer efficiencies compared to other transfection approaches [91] . Furthermore, using hepatocyte-specific ligands, more hepatocytespecific transfections can be achieved [132] .
Viral transduction
Transduction with viral particles covers a widely used methodology for gene transfer. Among the available viral vectors, retroviral and lentiviral vectors induce stable integration of the immortalization gene and thus generate sustained transgene expression in the progeny [132, 138] . Furthermore, these vectors do not provoke harmful immune responses and allow integration of large genes [139] . Retroviral vectors, such as the Mo-MLV-derived vectors, have been frequently used to establish human and rodent hepatic cell lines [2, 9, 19, 84, 87, [102] [103] [104] 108, 110, 111, 118, 119, 124, 140, 141] . A major flaw in this system is its inability to transduce non-dividing cells, which makes it unsuitable for non-proliferating cells, including hepatocytes [139, 142] . Even when growth factors are added to the cell culture medium to induce hepatocyte mitosis, the efficiency of transduction often remains limited [132, 139, 142, 143] . Lentiviral vectors derived from the human immunodeficiency virus (HIV) can tackle these issues and transduce both dividing and non-dividing cells by using virus at a relatively high titer [139, [142] [143] [144] . Moreover, lentiviral vectors can provide high transduction efficiencies without affecting the differentiated hepatic phenotype [139, 143, 145] . Although lentiviral vectors lack hepatocyte specificity, the use of hepatocyte specific promoters can restrict the expression of lentiviral genes to the parenchymal liver cells [144] . Several studies have demonstrated appropriate gene transfer for immortalization of human adult and fetal hepatocytes [7, 20, 23] . Rodent hepatocytes, especially murine hepatocytes are considerably resistant to HIV vectormediated transduction. This resistance has been related to a block in the immediate-early phase of infection [142] . In addition to the use of higher viral titers, cell culture medium supplied with growth factors, namely EGF and to a lesser extent HGF, was found to improve lentiviral transduction efficacy of primary mouse hepatocytes [142, 146] . Similarly, when transducing human adult and fetal hepatocytes, the use of growth factors markedly upregulated the expression of lentiviral genes. Consequently, this transduction approach offers the possibility to reduce the viral load, which as such lowers cost and reduces cellular toxicity [144] . Also the antioxidant, vitamin E proved to significantly enhance lentiviral transduction rates of human and rat adult hepatocytes [142] .
Human artificial chromosomes
The generation of a particular rat hepatic cell line was made possible by a more recent gene transfer method, namely through generation of a human artificial chromosome (HAC) [129, 147] . Although this method generally has lower transfer efficiency than the use of viral vectors, the HACs possess many properties of the ideal gene delivery vector. These include mitotically stable episomal maintenance and incorporation of large genes under control of their regulatory elements, allowing a correct, physiologically regulated transgene expression. Furthermore, due to their episomal nature, integration-related complications, such as oncogenesis, should be avoided [138] . Immortalization of human fibroblasts using HAC-mediated episomal expression of hTERT has also been described, potentially offering new perspectives for hepatocyte immortalization [148] .
Application of immortalized hepatic cell lines
It has repeatedly been postulated that immortalized hepatic cell lines, which could offer an unlimited supply of well-characterized, pathogen-free cells, may represent an attractive alternative for primary hepatocytes in several clinical applications as well as fundamental and applied research [106, 147, 149] . So far, multiple studies based on immortalized hepatocytes have already been performed.
Clinical application

Hepatocyte transplantation
The use of different animal models of hepatic impairment made it possible to demonstrate the therapeutic efficiency of transplanted cell lines. In this regard, it was shown that transplantation of conditional immortalized rat hepatocytes could protect portacaval-shunted rats from hyperammonemia-induced hepatic encephalopathy [119, 149] , improve survival of rats with acute liver failure (ALF) [125] , adjust for bilirubin conjugation defect in Gunn rats [150, 151] , and correct the global hepatic abnormalities associated with end-stage liver failure in cirrhotic animals [149] . Likewise, several human adult and fetal hepatic cell lines, including HHE6E7T1, NKNT-3, IHH, HepCL, 16T-3, and OUMS-29 were confirmed to promote survival in a pig [111] , rat [152] or mice [23, 124, 153] model of ALF. Furthermore, YOCK-13, an insulin-producing human hepatic cell line was reported to control diabetes when transplanted into totally pancreatectomized diabetic pigs [110] .
Bioartificial liver systems
For large-scale applications that rely on in vitro hepatic functionality, such as BAL systems, the development of a hepatic cell line that combines both in vitro hepatic function and proliferation capacity would be of great value.
Two human fetal hepatic cell lines, namely HepLi-4 and cBAL111, have already been evaluated as a potential cell source for BAL systems [87, 154] . However, it was revealed that both cell lines possessed insufficient hepatic functionality to be applicable for in vitro applications. The need for in vitro culture conditions that mimic the in vivo situation and promote hepatocyte differentiation in vitro was clearly emphasized [7, 87, 154] . This was further supported by experiments, which showed that cBAL111 cells are able to partly differentiate into functional hepatocytes once transplanted in vivo [7] .
Different human adult hepatic cell lines have also been proposed as possible candidates for BAL application, but as for the modified fetal hepatic cell line, OUMS-29/H-11, data on efficacy in animal models of severe liver failure are currently lacking [112, 141, [155] [156] [157] [158] . However, the production of ammonia [155] or possible inability to eliminate ammonia [141] are undesirable features for a BAL system [158] .
Another modified adult hepatic cell line, composed of TTNT cells overexpressing IL-1 Ra, has already been tested and was not able to improve survival of an ALF rat model [158] .
Fundamental and applied research
Nowadays, human and rodent hepatic cell lines, such as CWSV [159, 160] , H2.35 [161, 162] , NeHepLxHT [163] , OUMS-29 [164] , and THLE [165, 166] are still being used for fundamental research. In this regard, a lot of investigations related to hepatotropic viruses have been performed on TPH1 cells [167, 168] . Furthermore, a murine model of HBV viremia, based on immortalized human hepatocytes transfected with hepatitis B virus DNA, has been created and offers the opportunity for in vivo HBV studies [169] . Several hepatic cell lines have also proven useful as in vitro tools for screening and safety testing of drug candidates. For instance, Hc3716-hTERT cells represented the first model for predicting the side-effects of telomere-targeting drugs in normal cells and it was suggested that the Fa2N4 cell line could be used for routine screening during discovery for pregnane X receptor mediated CYP3A4 induction [108, 170] .
Conclusions and perspectives
In vitro expansion of human hepatocytes has gained considerable attention, as it might serve many clinical applications and fundamental research purposes. Prominent examples include the establishment of a bio-artificial human liver device that can be used to bridge the time until liver transplantation is possible and the creation of a liver-based in vitro tool for screening and safety testing of drug candidates. As freshly isolated and cultured mature hepatocytes inherently have very poor growth potential, efforts have focused on strategies to immortalize primary hepatocytes while maintaining their liver-specific functions. The currently available methods include transduction or transfection with prototypical immortalization genes and conditional immortalization by temperature-based regulation, recombinase-based control and transcriptional regulation. Although hepatocyte immortalization has been explored for years, it is still in its infancy since no cell lines with high in vivo-like hepatic functionality are yet available. As already postulated more attention should be paid to culture systems that support differentiation of the immortalized hepatocytes [6, 7, 87] . The past decade witnessed the introduction of novel strategies for cell immortalization, based on the use of cell cycle regulators to surmount the p16-regulated premature growth arrest, observed in several epithelial cells [171, 172] . Similarly, human myogenic cells immortalized by combined overexpression of hTERT, cyclin D1 and a mutant cdk4 isoform were able to overcome a p16-regulated precocious growth arrest without loss of their differentiation potential [173] . Although direct sequestration of p16 could not induce hepatocyte proliferation, it is worthwhile to examine the blocking of p16 control and pRB activity by overexpression of cell cycle regulators [20, 23] . A prerequisite to develop novel hepatocyte immortalization strategies is further fundamental research on the regulation of liver cell growth, especially in vitro. Such efforts should be strongly encouraged as they could lead to the generation of a robust hepatocyte-derived cell line with sustained liverspecific functionality resembling the in vivo situation. It can be anticipated that such a system will not only trigger a lot of interest among clinicians but also in the area of in vitro pharmacotoxicology.
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